JPMorgan Is Chasing India’s Deal Boom. Is JPM the Right Financial Stock to Own Now?
Dimon flew to Mumbai this week praising India’s growth while flagging its tax enforcement as a real problem for foreign investors.
Jensen Huang Is in the Room Where It Happens
Trump’s “AI Force” shifts Nvidia’s biggest policy risk in Washington.
Vertex Has a Nov. 30 FDA Date That Could Redefine It
Revenue is at $13 billion and growing. Povetacicept for kidney disease is the catalyst that decides whether VRTX is still a cystic fibrosis stock or something larger.
Nike Reports October 1 at a 12-Year Low. What Bulls Need to See.
With its S&P 100 exit effective Sept. 21, Q1 FY2027 is the first big test of Elliott Hill’s turnaround.
Salesforce Raised Its Revenue Target to $63 Billion. The Stock Is Still 34% Off Its High.
Dreamforce delivered hard numbers: Agentforce ARR up 240%, Q3 cRPO guidance at 14%, and a FY2030 target that more firms now believe.
Nucor’s Selloff Is About a Miss on the Street, Not a Miss in the Business
A roughly 6% drop after guidance that still shows accelerating earnings and record shipments is a cyclical investor’s moment to pay attention.
European Stocks Are 5% Below Strategists’ Christmas Target
Friday’s selloff left the Stoxx 600 at 635.45 while Bloomberg’s September survey (the most bullish since 2018) puts year-end at 670. Here’s what closes that gap and what could widen it.
Mortgage Rates Hit 6.95%. Here Is What It Costs a Buyer.
With real quotes nearer 7.2% and pending sales 30% below pre-pandemic norms, the math has turned against buyers and homebuilder shareholders alike.
US Energy and Farm Goods Are the Real Trade at Stake
With $30 billion in reciprocal tariff cuts being finalised ahead of Xi’s Washington visit, soybeans, LNG, and China-exposed equities are where positioning matters most.
CoreWeave’s $104 Billion Backlog Answers the Regulatory Scare
Data center moratoriums shook the stock. Contracts say demand held.